☆ 4.7 Editorial Material

Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice

EUROPEAN HEART JOURNAL (2023)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial

Joan Carles Trullas et al.

Summary: This study aims to evaluate whether adding hydrochlorothiazide (HCTZ) to intravenous furosemide is a safe and effective strategy for improving diuretic response in acute heart failure (AHF). The study found that adding HCTZ to loop diuretic therapy can improve diuretic response in patients with AHF, but may also lead to renal function impairment.

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Patients with Chronic Kidney Disease

William G. Herrington et al.

Summary: Empagliflozin therapy reduces the risk of disease progression or cardiovascular death in patients with chronic kidney disease.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors et al.

Summary: The sodium-glucose cotransporter 2 inhibitor empagliflozin improves clinical outcomes in patients hospitalized for acute heart failure, regardless of ejection fraction or the presence of diabetes.

NATURE MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)

P. Christian Schulze et al.

Summary: This study suggests that early addition of empagliflozin to standard diuretic therapy can increase urine output in patients with acute decompensated heart failure without affecting renal function.

CIRCULATION (2022)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S. D. Solomon et al.

Summary: The study shows that SGLT2 inhibitors are effective in reducing the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. However, whether they are effective in patients with a higher left ventricular ejection fraction remains uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Acetazolamide in Acute Decompensated Heart Failure with Volume Overload

Wilfried Mullens et al.

Summary: The addition of acetazolamide to loop diuretic therapy in patients with acute decompensated heart failure results in a higher incidence of successful decongestion without increasing adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the

Zachary L. Cox et al.

Summary: The DICTATE-AHF trial aims to evaluate the efficacy and safety of early initiation of dapagliflozin during acute heart failure hospitalization, comparing it to usual care. The trial will assess outcomes such as diuretic response, worsening heart failure, hospital readmission, NT-proBNP change, and safety endpoints.

AMERICAN HEART JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial

Milton Packer et al.

Summary: Empagliflozin significantly reduced the risk of heart failure-related inpatient and outpatient events in patients with heart failure with preserved ejection fraction, including cardiovascular death, heart failure hospitalization, and urgent visits, while also decreasing total heart failure hospitalizations and intensive care admissions. Patients receiving empagliflozin may experience improved New York Heart Association functional class levels.

CIRCULATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Theresa A. McDonagh et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Mark C. Petrie et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Effects of Serelaxin in Patients with Acute Heart Failure

Marco Metra et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure

M. Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials

Yuliya Lytvyn et al.

CIRCULATION (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure

Maria Rosa Costanzo et al.

JACC-HEART FAILURE (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical Effectiveness of Tolvaptan in Patients with Acute Decompensated Heart Failure and Renal Failure: Design and Rationale of the AQUAMARINE Study

Yuya Matsue et al.

CARDIOVASCULAR DRUGS AND THERAPY (2014)

Add to Collection

Review Cardiac & Cardiovascular Systems

Myocardial Recovery and the Failing Heart Myth, Magic, or Molecular Target?

Douglas L. Mann et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)

Add to Collection

Article Medicine, General & Internal

Effect of Nesiritide in Patients with Acute Decompensated Heart Failure

C. M. O'Connor et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Medicine, General & Internal

Effects of oral tolvaptan in patients hospitalized for worsening heart failure - The EVEREST outcome trial

Marvin A. Konstam et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)

Add to Collection

Article Cardiac & Cardiovascular Systems

Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure

Maria Rosa Costanzo et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.